---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-101737"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:33:50.445956+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology corporate presentation confirms LYMPHIR launch in Q4 2025; $400M+ market

## Summary
- LYMPHIR (denileukin diftitox) FDA-approved Aug 2024 for relapsed/refractory CTCL; first new systemic therapy since 2018.
- Commercial launch readiness nearing completion; ~$90M invested to date, 12-18 month inventory manufactured.
- New permanent J-code (J9161) secured; NCCN guidelines inclusion; sales force hiring underway.
- Clinical data: 36% ORR (9% CR, 27% PR), median 1.4 months to response, 6.5 months median duration of response.
- Ongoing combo studies: with KEYTRUDA (27% ORR in solid tumors) and CAR-T; prelim data expected Q4 2025/Q1 2026.

## SEC filing metadata
- accession: 0001213900-25-101737
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025101737/0001213900-25-101737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025101737/ea0262328-8k_citiusonc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-101737
- JSON: https://secwatch.observer/filing/0001213900-25-101737.json
- Plain text: https://secwatch.observer/filing/0001213900-25-101737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.